ZHZe-Lan Hu

Ze-Lan Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ze-Lan Hu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:

  • Jing Zheng

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    4 shared publications
  • Hong-Tao Wang

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    2 shared publications
  • Ji-Wei Liu

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    2 shared publications
  • Kui Li

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    2 shared publications
  • Xin Zhang

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    2 shared publications
  • Yong-Jie Liu

    Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

    2 shared publications

Latest Publications

  • β-Catenin is required for maintaining hippocampal morphology during the perinatal period

    by H.-T. Wang, L. Zeng, Q. Chen, X. Zhang, J.-W. Liu, T.-J. Lu, Z.-Q. Xiong, J. Zheng, Z.-L. Hu


  • Inactivation of β-catenin results in the reduction of postnatal body weight gain

    by Hong-Tao Wang, Lin Zeng, Xin Zhang, Kui Li, Yong Zu, Ji-Wei Liu, Yong-Jie Liu, Zhi-Chuan Zhu, Zhi-Qi Xiong, Jing Zheng, et al.


  • Erratum to: ZFX regulates glioma cell proliferation and survival in vitro and in vivo

    by Zhichuan Zhu, Kui Li, Dafeng Xu, Yongjie Liu, Hailiang Tang, Qing Xie, Liqian Xie, Jiwei Liu, Hongtao Wang, Ye Gong, et al.


    • 1 January 2013
      • Vol. 6  (11) , 2460-2467

    ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299

    by Kui Li, Zhi-Chuan Zhu, Yong-Jie Liu, Ji-Wei Liu, Hong-Tao Wang, Zhi-Qi Xiong, Xu Shen, Ze-Lan Hu, Jing Zheng

    ZFX (zinc finger transcription factor, X chromosome-linked) contributes to the maintenance of different types of stem cells and the progression of various cancers. We have previously reported that ZFX knockdown inhibits proliferation of glioma in vitro and in vivo. Since overexpression of ZFX in lung cancer tissue correlates with lymph node metastasis, we hypothesized that ZFX may play a role in lung cancer. In this study, we identified ZFX as a promoter of lung cancer growth and migration in a NSCLC (non-small cell lung carcinoma) cell line H1299. ZFX knockdown caused proliferation inhibition determined by MTT assay and colony formation assay, G0/G1 arrest of cell cycle and slightly increased proportion of apoptotic cells assessed by flow cytometry assay, decreased population of migrating cells showed by wound-healing assay, increased cell senescence evidenced by senescence-associated beta-galactosidase staining. ZFX knockdown also led to decreased proportion of tumor bearing mice and reduced mean tumor volume in a subcutaneous tumor model. In addition, western blot showed that ZFX knockdown down regulated a set of proteins involved in proliferation, survival and motility. Altogether, these results suggest that ZFX may be a potential therapeutic target for NSCLC.


  • Inducible Prrxl1‐CreERT2 recombination activity in the somatosensory afferent pathway

    by Ze‐Lan Hu, Ying Huang, Xiao‐Rong Tao, Zheng‐Han Qi, Jia‐Yin Chen, Yu‐Qiang Ding

    Prrxl1‐CreERT2 transgenic mice expressing tamoxifen‐inducible Cre recombinase were generated by modifying a Prrxl1‐containing BAC clone. Cre recombination activity was examined in Prrxl1‐CreERT2; Rosa26 reporter mice at various embryonic and postnatal stages. Pregnant mice were treated with a single dose of tamoxifen at embryonic day (E) 9.5 or E12.5, and X‐gal staining was performed 2 days later. Strong X‐gal staining was observed in the somatosensory ganglia (e.g., dorsal root and trigeminal ganglia) and the first central sites for processing somatosensory information (e.g., spinal dorsal horn and trigeminal nerve‐associated nuclei). When tamoxifen was administered at postnatal day (P) 20 or in adulthood (P120), strong Cre recombination activity was present in the primary somatosensory ganglia, while weak Cre recombination activity was found in the spinal dorsal horn, mesencephalic trigeminal nucleus, principal sensory trigeminal nucleus, and spinal trigeminal nucleus. This mouse line provides a useful tool for exploring genes' functions in the somatosensory system in a time‐controlled way. genesis 50:552–560, 2012.


  • Open Access

    The role of the transcription factor Rbpj in the development of dorsal root ganglia

    by Ze-Lan Hu, Ming Shi, Ying Huang, Min-Hua Zheng, Zhe Pei, Jia-Yin Chen, Hua Han, Yu-Qiang Ding

    Background: The dorsal root ganglion (DRG) is composed of well-characterized populations of sensory neurons and glia derived from a common pool of neural crest stem cells (NCCs), and is a good system to study the mechanisms of neurogenesis and gliogenesis. Notch signaling is known to play important roles in DRG development, but the full scope of Notch functions in mammalian DRG development remains poorly understood. Results: In the present study, we used Wnt1-Cre to conditionally inactivate the transcription factor Rbpj, a critical integrator of activation signals from all Notch receptors, in NCCs and their derived cells. Deletion of Rbpj caused the up-regulation of NeuroD1 and precocious neurogenesis in DRG early development but led to an eventual deficit of sensory neurons at later stages, due to reduced cell proliferation and abnormal cell death. In addition, gliogenesis was delayed initially, but a near-complete loss of glia was observed finally in Rbpj-deficient DRG. Furthermore, we found P75 and Sox10, which are normally expressed exclusively in neuronal and glial progenitors of the DRG after the NCCs have completed their migration, were co-expressed in many cells of the DRG of Rbpj conditional knock-out mice. Conclusions: Our data indicate that Rbpj-mediated canonical Notch signaling inhibits DRG neuronal differentiation, possibly by regulating NeuroD1 expression, and is required for DRG gliogenesis in vivo.